Skip to content

INSOLE – Randomized Controlled Trial on the Effectiveness of a Structured Exercise Programme Compared with Custom-Made Orthotic Insoles

INSOLE – Randomized Controlled Trial on the Effectiveness of a Structured Exercise Programme Compared with Custom-Made Orthotic Insoles - INSOLE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00040710
Enrollment
280
Registered
2026-06-26
Start date
2026-08-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Foot pain, functional impairments of the foot, and/or foot deformities in adults with long-term use of custom-made orthotic insoles.

Interventions

Group 1: Participants allocated to the intervention group will take part in a structured home-based foot exercise programme over a period of 10 weeks. The programme aims to strengthen the intrinsic fo

Sponsors

Philipps-Universität Marburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Long-term use (= 6 months) of custom-made orthotic insoles prescribed by a physician and manufactured by an orthopaedic technician • Orthotic insoles prescribed for at least one of the following indications: pes planus, planovalgus deformity and/or splayfoot hallux valgus plantar fasciitis (with or without calcaneal spur) metatarsalgia (forefoot pain) non-specific foot pain • No foot pain on most days during the previous three months • Ability and willingness to participate in a structured home-based exercise programme • Sufficient German language skills to understand study procedures, questionnaires, and exercise instructions • Ability to provide written informed consent • Written informed consent provided prior to study participation

Exclusion criteria

Exclusion criteria: Participants will be excluded if any of the following criteria apply: • Severe congenital foot deformities (e.g. clubfoot or pes cavus) • Orthotic insoles prescribed primarily due to leg length discrepancy • Post-traumatic conditions or structural damage affecting the foot or ankle • Achilles tendon disorders or posterior heel pain (e.g. Haglund deformity) • Predominant musculoskeletal conditions outside the foot (e.g. knee, hip, or back disorders) that may substantially affect gait or participation in the intervention • Acute foot pain or inflammatory conditions of the lower extremity • Severe neurological or systemic diseases affecting foot function, mobility, or pain perception (e.g. advanced polyneuropathy or inflammatory rheumatic diseases)

Design outcomes

Primary

MeasureTime frame
Foot pain and function assessed using the German version of the Foot Function Index (FFI-D; Foot Function Index – German Version). The FFI-D total score (range 0–100; higher scores indicate greater pain and functional impairment) will be assessed at T0 (baseline) , T1 (10 weeks after baseline) and T2 (6-month follow-up) The primary analysis will be based on the difference in responder rates between groups. Participants will be classified as responders or non-responders according to predefined criteria derived from changes in the FFI-D total score between T0 and T1.

Secondary

MeasureTime frame
Pain intensity, assessed using a Visual Analogue Scale (VAS), at T0 (baseline), T1 (10 weeks), and T2 (6-month follow-up). Health-related quality of life, assessed using the EQ-5D-5L (EuroQol 5 Dimensions, 5 Levels), at T0, T1, and T2. Patient satisfaction with the assigned intervention, assessed using a study-specific questionnaire at T1. Adherence to the exercise programme and successful discontinuation of orthotic insole use, assessed through weekly self-reports and study-specific questionnaires during the intervention period and at T1 and T2. Foot morphology, assessed using the Foot Scan System (FS-Systeme, Germany). Parameters include foot length and the Chippaux-Smirak Index (CSI). Measurements will be performed at T0 (baseline), T1 (10 weeks), and T2 (6-month follow-up). Continuous changes in these parameters over time will be analysed. Health economic outcomes, including healthcare utilisation, direct and indirect costs, and quality-adjusted life years (QALYs), assessed using participant questionnaires and the EQ-5D-5L at T0, T1, and T2. Implementation-related outcomes (intervention reach, fidelity, dose, mechanism of impact, and contextual factors), assessed within a mixed-methods process evaluation using questionnaires and qualitative interviews following completion of the intervention (T1).

Countries

Germany

Contacts

Public ContactAnnika Viniol

Philipps-Universität Marburg, Institut für Allgemeinmedizin

annika.viniol@uni-marburg.de+49 06421-2865130

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026